Skip to main
PEPG

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PepGen is a clinical-stage biotechnology company that holds significant potential in the treatment of neuromuscular and neurologic diseases with its Enhanced Delivery Oligonucleotide platform. The completion of enrollment in the 10mg/kg multi-dose cohort in the FREEDOM2 study is a positive development and the upcoming 2H26 data readout is a key catalyst for the company. While there were concerns with the earlier 5mg/kg PGN-EDODM1 data, the observed increase in drug concentrations over time and the management's comments on the safety profile are reassuring.

Bears say

PepGen is facing several challenges, such as the need for additional external funding to advance their development platform, safety concerns with two subjects experiencing transient albuminuria, and delays in their development plan due to the need for more investigation. Additionally, the company's valuation discount rate has increased to 40% due to safety being a key driver for advancement. This lowered target price to $5 from $9 reflects the uncertainty surrounding their pipeline and their need to resolve a clinical hold with the FDA.

PepGen Inc (PEPG) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Strong Buy based on their latest research and market trends.

According to 6 analysts, PepGen Inc (PEPG) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.